Surgical complications in oral and maxillofacial procedures occur in 1-15% of extractions depending on complexity, requiring comprehensive understanding of incidence rates, pathophysiology, recognition patterns, and evidence-based management protocols for optimal patient outcomes and medico-legal protection.
Hemorrhage Control and Management
Post-operative hemorrhage complicates 1-2% of routine extractions and 5-8% of surgical removals of impacted third molars, with severity ranging from minor oozing lasting 24-48 hours to serious bleeding requiring hospitalization. Immediate intraoperative hemorrhage management requires sustained direct pressure using gauze saturated with 1:50,000 or 1:100,000 epinephrine solution (topical epinephrine concentration of 0.1-0.2mg per 4x4 gauze) applied for 5-10 minutes with patient supine position facilitating dependent hemorrhage. Persistent bleeding requires evaluation for uncontrolled vessel, with direct ligation of bleeding vessels using absorbable suture (4-0 or 5-0 chromic gut) preferred for deep vessels, while superficial vessels respond to electrocautery at 25-35 watts setting with brief contact minimizing collateral thermal injury.
Secondary hemorrhage occurring 24-72 hours post-operatively results from clot displacement through inadequate hemostasis or patient activity disrupting platelet plug, requiring re-evaluation under direct visualization and hemostatic measures including gelatin sponge (Gelfoam) packing into extraction site with overlying 4-0 chromic suture securing material, and tranexamic acid (500mg tablet) placed intra-alveolarly dissolving at 50mg/hour absorption rate over 10 hours. Persistent hemorrhage exceeding 5-10 minutes despite conservative measures requires consideration of coagulopathy (prothrombin time >14 seconds, activated partial thromboplastin time >35 seconds, platelet count <100,000/μL) with appropriate laboratory testing and medical consultation. Patient counseling emphasizes pressure maintenance, head elevation at 45 degrees, avoidance of straws and rinsing for 24 hours, and ice application 15 minutes on, 15 minutes off for 6 hours to maintain local vasoconstriction.
Infection and Alveolar Osteitis (Dry Socket)
Surgical site infections occur in 2-5% of routine extractions and 5-15% of impacted third molar removal, with infection severity ranging from superficial wound cellulitis (erythema, warmth, minimal purulence) to serious deep space involvement (Ludwig's angina, descending necrotizing mediastinitis). Early infection detection within 48-72 hours post-operation requires clinical evaluation for fever (>38.5 degrees Celsius), localized swelling exceeding normal post-operative edema, purulent exudate, and lymphadenopathy with differential diagnosis including normal post-operative inflammation (peaks at 48-72 hours, resolves by 5-7 days) versus true infection requiring intervention.
Antibiotic prophylaxis reduces surgical site infection incidence by 40-50% in clean-contaminated procedures, with amoxicillin-clavulanate (875-125mg orally 1 hour pre-operation, continued 500mg three times daily for 3-5 days) or clindamycin (600mg pre-operation, 300mg three times daily for 3-5 days in penicillin-allergic patients) demonstrating superior efficacy to single-dose prophylaxis. Alveolar osteitis (dry socket) occurs in 3-5% of routine extractions and 15-30% of surgical extractions, particularly in impacted third molars, with incidence dramatically elevated in female patients taking oral contraceptives (relative risk 1.5-3.0) and smokers (relative risk 2.0-4.0). Prevention protocols including intra-alveolar placental-derived growth factor (platelet-derived growth factor, bone morphogenetic protein) or chlorhexidine rinse (0.12% for 5 minutes pre-operatively) reduce alveolar osteitis incidence by 40-60%.
Dry socket management requires aggressive irrigation with sterile saline at 3-5 liters per minute pressure using 18-gauge needle to remove necrotic tissue and bacterial biofilm, followed by placement of medicated dressing (zinc oxide eugenol, iodoform-based paste) maintained for 3-7 days with regular dressing changes every 24-48 hours. Oral antibiotic therapy (same protocols as above) addresses secondary bacterial colonization, while NSAIDs (ibuprofen 400-600mg every 4-6 hours) and paracetamol (500-1000mg every 6 hours) manage pain, with peak discomfort resolution within 3-5 days following aggressive management.
Nerve Injury - Inferior Alveolar and Lingual Nerve Complications
Temporary paresthesia of the inferior alveolar nerve (IAN) and lingual nerve occurs in 0.5-2% of routine extractions and 5-8% of impacted third molar removals, with permanent nerve injury incidence of 0.1-0.5% for routine extraction and 1-3% for surgical extraction of impacted molars. Lingual nerve injury results from surgical trauma, particularly excessive retraction or dissection during flap elevation, presenting with sensory dysfunction (hypoesthesia or paresthesia) of anterior 2/3 of tongue and lingual alveolar ridge, affecting taste sensation (fungiform papillae innervation) and affecting swallowing comfort and oral intake.
Inferior alveolar nerve injury from direct trauma, prolonged pressure, or stretching during tooth removal presents with immediate numbness of ipsilateral lower lip, anterior mandible, and anterior 2/3 of tongue. Nerve injury severity classification includes neurapraxia (mild compression, conduction block without axonal damage, recovery within 3-6 weeks), axonotmesis (moderate injury with axonal disruption but preserved nerve sheath, recovery within 3-6 months), and neurotmesis (complete nerve transection, requiring surgical nerve repair with 40-60% sensory restoration at best). Early intervention within 72 hours of recognized nerve transection permits microsurgical nerve repair using 10-0 nylon suture under operative microscope, with better outcomes than delayed repair after 2-4 weeks.
Management of temporary paresthesia includes patient reassurance (85-90% recovery within 3-6 months), oral anesthetic rinse (viscous lidocaine 2% for 30-60 seconds, 3-4 times daily) managing dysesthesia discomfort, and neurosensory testing at 1, 2, 3, and 6 months post-injury documenting recovery trajectory. Permanent paresthesia recovery potential decreases substantially beyond 6-12 months, with only 10-20% achieving meaningful sensation recovery after 12-24 months, necessitating psychological counseling and behavioral adaptation including careful eating technique (checking buccal mucosa for injury risk) and dentition surveillance.
Oroantral Communication (OAC) and Maxillary Sinus Involvement
Oroantral communication develops in 1-2% of routine maxillary molar extractions and 5-15% of impacted maxillary molar surgical removal, with perforation size less than 2mm spontaneously healing in 65-75% of cases through natural granulation and epithelialization over 3-4 weeks. Larger defects (2-5mm) require primary closure, with immediate surgical closure within 24 hours of recognition permitting layered repair using palatal mucosa flap (pedicled flap preserving blood supply) sutured over perforation with 3-0 chromic suture in interrupted pattern providing tension-free coverage reducing infection risk (5-8% infection rate with closure vs. 20-30% without closure).
Surgical flap procedures (Caldwell-Luc antrostomy) may be necessary for defects exceeding 5mm or those with significant bone loss, requiring bone graft (mineralized cancellous bone chips, demineralized freeze-dried bone allograft at 0.5-1.0cm dimensions) consolidation within graft bed creating 3-4mm height scaffold supporting mucosa flap placement. Oroantral fistula (persistent communication with chronic sinusitis) develops in 2-5% of untreated OAC, presenting with chronic purulent drainage, nasal congestion, and recurrent sinusitis (bacterial culprits including Streptococcus pneumoniae, Haemophilus influenzae, anaerobes), managed through definitive surgical closure with bone graft support and palatal flap rotation.
Pre-operative recognition of OAC risk factors including maxillary bone thickness less than 2-3mm (evaluated on CT imaging using Hounsfield units 300-400 for corticated bone), molar proximity to sinus floor (distance less than 1mm on panoramic radiographs), and extensive alveolar bone loss from periodontal disease enables preventive strategies including minimally invasive extraction technique limiting bone removal, use of anesthetic solutions without epinephrine (epinephrine causes vasoconstriction obscuring bleeding indicator of perforation), and intra-operative endoscopy (4mm rigid scope) confirming sinus integrity.
Mandibular Fracture During Extraction
Pathologic mandibular fractures develop in less than 0.1% of routine extractions but occur in 0.5-2% of surgical extraction cases with pre-existing mandibular bone atrophy, periapical pathology, or previous irradiation reducing bone density and mechanical strength. Risk factors include age greater than 65 years (increased fragility, decreased bone density), severe horizontal bone loss from periodontal disease reducing remaining bone height below 15-20mm, and presence of large periapical lesions weakening bone integrity through osteolytic destruction.
Prevention strategies include conservative tooth extraction minimizing traumatic force application, preservation of buccal cortical plate through careful flap design, and judicious use of bone removal limited to direct tooth visualization pathways. Fractures recognized intra-operatively require immediate non-operative management with gentle instrumentation avoiding further displacement, followed by panoramic radiographs confirming fracture extent and positioning. Uncomplicated non-displaced fractures heal reliably with soft diet (mechanical soft foods requiring minimal mastication), analgesic therapy (ibuprofen 400-600mg every 4-6 hours), and follow-up radiographs at 4 weeks confirming callus formation and bone union progression.
Displaced fractures require open reduction and internal fixation using compression plating (2.0mm dynamic compression plate with minimum 4 cortices on each fracture side), with pantograph registration and intermaxillary fixation using arch bars and elastics (elastic force 150-200 grams per side) for 4-6 weeks maintaining post-operative occlusion stability. Panoramic radiographs at 3 months post-fixation confirm complete bony union, with plates remaining in situ indefinitely unless mechanical complications develop.
Systemic Complications and Anesthetic Reactions
Vasovagal episodes occur in 1-3% of surgical cases, presenting with sudden onset syncope 2-30 minutes post-operatively precipitated by pain, anxiety, or sight of blood, managed through immediate patient positioning (Trendelenburg position with legs elevated above heart), cessation of surgical stimulation, assessment of airway patency, oxygen administration at 3-5 liters per minute, and establishment of intravenous access for emergency medication administration if required.
Allergic reactions to local anesthetic agents (particularly methyl paraben preservatives at 0.1-0.2% concentration in multidose vials) present with urticaria (hives), angioedema of lips and tongue, bronchospasm, and anaphylaxis (hypotension, syncope, airway compromise) requiring immediate epinephrine intramuscular injection (0.3-0.5mg of 1:1000 aqueous solution in adults, 0.01mg/kg in children) followed by oxygen supplementation, antihistamine administration (diphenhydramine 25-50mg IV), and corticosteroid therapy (methylprednisolone 125mg IV) preventing biphasic anaphylactic reactions occurring 12-24 hours later.
Pulmonary aspiration of blood, bone fragments, or instruments occurs in less than 0.1% of oral surgery cases but constitutes potentially serious airway emergency requiring immediate cessation of surgery, patient positioning (Trendelenburg, left lateral decubitus), suctioning of accessible debris, and emergency evaluation with laryngoscopy and bronchoscopy for object localization and removal. Post-operative aspiration pneumonia (fever, cough, hypoxia developing 12-48 hours post-operatively) requires chest radiography and broad-spectrum antibiotic therapy (amoxicillin-clavulanate 875mg three times daily or respiratory fluoroquinolone) targeting oral anaerobes and aerobic pathogens common in aspirated oral flora.